SRPT Advisory Committee to meet April 25. VCEL meets endpoint in Phase 2b trial + updates for BDSI ANTH BLRX CARA CERU FCSC FLXN FPRX GALE HSGX OCUL OMED SYN THLD TKAI

Mar 11, 2016 No Comments by

Updates to the Company Pipeline Database for March 10, 2016 are as follows. Refer to the FDA Calendar for upcoming catalysts: Ticker Price Drug Indication Stage Summary BDSI 3.40 Clonidine gel Painful diabetic neuropathy (PDN) Phase 2b Phase 3 trial failed to meet primary endpoint late March 2015. New trial initiated late 2015. Data due from Phase 2b trial […]

Daily News Read more

Latest biotech updates for week ended March 20

Mar 22, 2015 No Comments by

Latest updates to the Company Pipeline Database for the week ending March 20. Refer to the FDA Calendar for upcoming catalysts: Ticker Price Drug Indication Stage Link Text Updated ACRX 4.15 ARX-04 Moderate-to-severe acute pain Phase 3 Phase 3 trial initiated March 2015. Data due 4Q 2015 3/22/2015 ANTH 4.34 Blisibimod Lupus Phase 3 Missed primary endpoints […]

Daily News Read more


Feb 12, 2015 No Comments by

Latest updates to the Company Pipeline Database for February 9-11, 2015. Refer to the FDA Calendar for upcoming catalysts: Ticker Price Drug Indication Stage Link Text Updated AMAG 40.05 Makena – single-dose (1 mL) vial Reduce the risk of preterm birth in women with a singleton pregnancy PDUFA FDA decision due 2Q 2015 2/12/2015 AMGN […]

Daily News Read more

TRGT fails Phase 2b. Positive news for SLXP PGNX EXEL. Phase 3 data due soon for ADHD ZSPH + AERI SGYP VTUS ANTH GNCA updates

Jul 15, 2014 No Comments

Targacept, Inc. (NASDAQ: TRGT) announced that it did not meet the primary endpoint in their Phase 2b monotherapy trial of TC-1734 as a treatment for mild to moderate Alzheimer’s disease. Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) and Progenics Pharmaceuticals(NASDAQ:PGNX) announced that the FDA has informed Salix that RELISTOR Subcutaneous Injection, for the treatment of opioid-induced constipation (OIC) in patients taking opioids for chronic […]

Read more


Oct 29, 2013 No Comments

The following companies released pipeline updates with their 3Q financial results on Tuesday. Summary as follows: CytRx Corporation (NASDAQ: CYTR) $2.52 4Q13 – initiate a Phase 2 trial with aldoxorubicin in patients with relapsed glioblastoma. 4Q13 – initiate a Phase 2 trial of aldoxorubicin in treating AIDS-related Kaposi’s sarcoma. December 2013 – report top-line progression-free survival results […]

Read more

CTIC Tosedostat placed on partial clinical hold. CYTK reverse split. CYTR aldoxorubicin data due 2H 2013 + PBMD ANTH updates

Jun 25, 2013 No Comments

Cell Therapeutics, Inc. (NASDAQ:CTIC) was informed by the FDA that a partial clinical hold has been placed on Tosedostat, for the treatment of blood-related cancers. This follows the death of a patient from myocarditis. The FDA has requested additional data on patients treated with Tosedostat, including additional information about the patient that died. These data will […]

Read more

FURX FDA Approval. THLD initiates Phase 3 pancreatic trial. IMGN pipeline update + ANTH

Jan 27, 2013 No Comments

Furiex Pharmaceuticals, Inc. (NASDAQ: FURX) said that Takeda Pharmaceutical Company Limited received approval from the FDA for three new type 2 diabetes therapies, NESINA (alogliptin) and the fixed-dose combination therapies, OSENI (alogliptin and pioglitazone) and KAZANO (alogliptin and metformin HCl), for the treatment of type 2 diabetes in adults as adjuncts to diet and exercise. […]

Read more

BIIB positive Phase 3 data. CBST pipeline update.ANTH offering + SGEN ARIA ACOR news

Jan 25, 2013 No Comments

Biogen Idec (NASDAQ: BIIB) announced that it met the primary endpoint, the annualized relapse rate (ARR) at one year, for both the two-week and four-week doses in its Phase 3 pivotal clinical trial, ADVANCE, of peginterferon beta-1a as a potential treatment for relapsing-remitting multiple sclerosis (RRMS). It also mentioned that it met the secondary endpoints of risk of 12-week […]

Read more

TRGT fails Phase 2 ADHD. OXGN SPA agreement for Phase 3 ATC trial. ANTH plans Phase 3 lupus trial

Sep 18, 2012 2 Comments

Targacept, Inc. (NASDAQ: TRGT) today announced it failed its Phase 2 trial of TC-5619 as a treatment for inattentive-predominant attention deficit/hyperactivity disorder (ADHDi). OXiGENE, Inc. (Nasdaq:OXGN) announced that it has come to agreement with the FDA on a Special Protocol Assessment (SPA) for its Phase 3 clinical trial (FACT 2) of ZYBRESTAT for the treatment of anaplastic thyroid […]

Read more

BPAX closes offering. PCYC $50m milestone. RGLS pending IPO. ANTH to vote to raise authorized shares

Aug 20, 2012 No Comments

BioPharmCatalyst is back with daily updates. BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) announced the closing of the sale of 2,359,932 shares of its common stock and warrants to purchase up to 1,179,966 additional shares for net proceeds of approximately $3.3 million. Pharmacyclics, Inc. (Nasdaq: PCYC) announced that the clinical trial, SPARK (MCL2001), of ibrutinib in patients with relapsed […]

Read more

ONXX receives FDA Approval. SGEN and ASTX granted positive CHMP recommendations. ANTH and SOMX offering details + PSDV SGYP ARRY news

Jul 20, 2012 No Comments

Onyx Pharmaceuticals (Nasdaq: ONXX) today announced that it received accelerated approval from the FDA for Kyprolis (carfilzomib) for Injection, for the treatment of patients with multiple myeloma who have received at least two prior therapies, including bortezomib and an immunomodulatory agent, and have demonstrated disease progression on or within 60 days of completion of the last therapy. Ligand […]

Read more